Repare Therapeutics announces positive Phase 1 Minotaur trial results for advanced solid tumors, with 18.2% overall response rate for Lunresertib combined with Folfiri.
Repare Therapeutics announces positive Phase 1 Minotaur trial results for advanced solid tumors. Lunresertib combined with Folfiri showed an 18.2% overall response rate and 51.5% clinical benefit in heavily pretreated patients. The trial aimed at safety, tolerability, and determining Phase 2 dose and schedule. Early efficacy and potential treatment duration advantage warrant further study.
June 26, 2024
3 Articles